Lombard, Louise
Farrar, Mallory
Ye, Wenyu
Kim, Yongin
Cotton, Sarah
Buchanan, Andrew S.
Jackson, James
Joshi, Shivang
Funding for this research was provided by:
Eli Lilly and Company
Article History
Received: 3 February 2020
Accepted: 15 April 2020
First Online: 29 April 2020
Ethics approval and consent to participate
: Patients provided informed consent for use of their anonymized and aggregated data for research and publication in scientific journals by means of a check box on the front page of the PSC.There was no need to seek ethical approval for Disease Specific Programmes. The study methods are covered under the EphMRA code of conduct, which covers the EU, USA and other countries. This states that market research “relating to market or consumer behavior of the sort that pharmaceutical companies routinely commission, whether involving healthcare professionals, patients, carers, or members of the public does not require Clinical Research Ethics Committee or Independent Review Board approval (Institutional Review Board in the USA)”. However, the DSP methodology and questionnaires were reviewed by an official independent body, Freiburger Ethik-Kommission International (FEKI), which granted ethical approval.
: Not applicable.
: LL: employee and shareholder of Eli Lilly and Company, Indianapolis, IN, USA.MF: former Lilly employee; shareholder of Eli Lilly and Company, Indianapolis, IN, USA.WY: employee and shareholder of Eli Lilly and Company, Indianapolis, IN, USA.YK: employee and shareholder of Eli Lilly and Company, Indianapolis, IN, USA.ASB: employee and shareholder of Eli Lilly and Company, Indianapolis, IN, USA.SC: employee of Adelphi Real World, Bollington, UK.JJ: employee of Adelphi Real World, Bollington, UK.SJ: has received honoraria for contribution to an advisory board and speaker’s bureau from Eli Lilly and Company.